JMP Securities Life Sciences Conference (Live)
06/19/19 at 12:00 p.m. ET
BMO 2019 Prescriptions for Success Healthcare Conference (Live)
06/25/19 at 11:00 a.m. ET
Corporate ProfileNeos Therapeutics develops, manufactures, and commercializes innovative extended-release (XR) products using our proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technology platforms. We have three approved ADHD products, two of which use our ODT technology and one of which is an extended-release (ER) oral suspension. Our growing ADHD product portfolio puts Neos in a unique position to help meet the different needs of patients that struggle with ADHD.
- 06/12/19Neos Therapeutics to Present at Two Upcoming June Conferences
- 05/30/19Neos Therapeutics to Present at the Jefferies 2019 Global Healthcare Conference
- 05/09/19Neos Therapeutics Reports First Quarter 2019 Financial Results
- 05/02/19Neos Therapeutics to Host First Quarter 2019 Financial and Operating Results Conference Call on May 9th, 2019
Corporate Whistleblower Hotline
Report online: http://www.openboard.info/NEOS/
Call toll-free: (844) 375-8324 (24 hours a day, 7 days a week)
Anytime, from any location. You DO NOT have to give your name.